First thalidomide clinical trial in multiple myeloma: A decade

Frits Van Rhee, Madhav Dhodapkar, John D. Shaughnessy, Elias Anaissie, David Siegel, Antje Hoering, Jerome Zeldis, Bonnie Jenkins, Seema Singhal, Jayesh Mehta, John Crowley, Sundar Jagannath, Bart Barlogie*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

41 Scopus citations

Abstract

The clinical outcomes of 169 patients enrolled in the first clinical trial of thalidomide for advanced or refractory myeloma are updated. Seventeen patients remain alive and 10 are event-free, with a median follow-up of 9.2 years. According to multivariate analysis of pretreatment variables, cytogenetic abnormalities, present in 47% of patients within 3 months of enrollment, and γ light chain isotype both affected overall survival and event-free survival adversely. Forty percent of the 58 patients lacking these 2 unfavorable features, one-half of whom had no disease recurrence, survived at least 6 years, in contrast to fewer than 5% among those with 1 or 2 risk features (P < .001). Patients who had received cumulative thalidomide doses in excess of 42 g in the first 3 months enjoyed superior overall and event-free survival. The poor outcome associated with λ-type myeloma may relate to its overrepresentation in molecularly defined high-risk disease gleaned from studies in newly diagnosed myeloma.

Original languageEnglish (US)
Pages (from-to)1035-1038
Number of pages4
JournalBlood
Volume112
Issue number4
DOIs
StatePublished - Aug 15 2008

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'First thalidomide clinical trial in multiple myeloma: A decade'. Together they form a unique fingerprint.

Cite this